Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

1

Sintilimab and Pembrolizumab were compared for hepatic safety in patients with advanced non-small cell lung cancer (NSCLC).
2

The study included 222 patients treated with either Sintilimab or Pembrolizumab, with no significant differences in combination chemotherapy regimens.
3

The overall incidence of hepatic-related adverse events was 17.1% for Sintilimab and 18.1% for Pembrolizumab, showing no significant differences.
4

Kaplan-Meier analysis indicated similar risks of hepatotoxicity between Sintilimab and Pembrolizumab, with no Grade 3 or higher events observed.
5

The findings suggest comparable hepatic safety profiles for Sintilimab and Pembrolizumab in advanced NSCLC, warranting further validation in larger studies.

Frontiers In Immunology

by Pan Ma, Yumeng Zhou, Xin Zhang, Quanfeng Zhao, Yu Peng, Hailong Jiang, Linli Xie, Yan Liao
June 24, 2026

1